- Home
- SCNI vs CNSP Comparison
SCNI vs CNSP Comparison
Compare SCNI & CNSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SCNI | CNSP |
|---|---|---|
| Founded | 2003 | 2017 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.6M | 4.3M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SCNI | CNSP |
|---|---|---|
| Price | $0.94 | $7.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $20.00 |
| AVG Volume (30 Days) | ★ 41.7K | 10.3K |
| Earning Date | 11-24-2025 | 11-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.26 | N/A |
| Revenue | ★ $1,147,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $4.55 | ★ N/A |
| Revenue Growth | ★ 303.87 | N/A |
| 52 Week Low | $0.86 | $4.93 |
| 52 Week High | $6.18 | $114.00 |
Technical Indicators
Market Signals| Indicator | SCNI | CNSP |
|---|---|---|
| Relative Strength Index (RSI) | 38.13 | 48.63 |
| Support Level | $1.14 | $6.11 |
| Resistance Level | $1.26 | $8.10 |
| Average True Range (ATR) | 0.10 | 0.52 |
| MACD | 0.02 | 0.13 |
| Stochastic Oscillator | 13.13 | 47.24 |
Price Performance
Historical ComparisonAbout SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units, one focused on in-house development of inflammation and immunology (I&I) biological therapeutic products beginning with a pipeline of nanosized VHH antibodies (NanoAbs) targeting diseases with large unmet medical needs, and the other a boutique CDMO providing services to help biotech companies efficiently bring their products to market by leveraging Scinai's drug development and GMP and non-GMP manufacturing capabilities for pre-clinical and clinical studies. The company generates maximum revenue from the provision of CDMO (Contract Development and Manufacturing Organization) services.
About CNSP CNS Pharmaceuticals Inc.
CNS Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. It is involved in the development of Berubicin, which is a therapy for the treatment of glioblastoma. Glioblastomas are tumors that arise from astrocytes, which are star-shaped cells that make up the supportive tissue of the brain.